Zinpentraxin alfa Medicine 05 December 2023 Extended indication Idiopathic Pulmonary Fibrosis (IPF) Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Zinpentraxin alfa Domain Lung diseases Reason of inclusion New medicine (specialité) Main indication Lung diseases other Extended indication Idiopathic Pulmonary Fibrosis (IPF) Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Roche Portfolio holder Roche Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks A recombinant form of human pentraxin-2 protein able to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date 2024 Expected Registration 2025 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times every 4 weeks Dosage per administration 10 mg/kg References NCT04594707, NCT04552899 Additional remarks Expected patient volume per year Patient volume < 2,040 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Jaarverslag Longfibrosepatiëntenvereniging 2017 (1) Additional remarks Er zijn ongeveer 3.400 longfibrose patiënten in Nederland 60% daarvan heeft IPF. Dit komt neer op 2.040 IPF patiënten. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Phase II: Myelofibrosis References SPS UK Additional remarks Other information Additional remarks